Year: 2020
Language: English
Author(s): World Federation of Hemophilia
In this session from the WFH 2020 Virtual Summit, Declan Noone, Len Valentino, Kate Khair and Ed Kuebler discuss:
The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.
The WFH does not promote any particular pharmaceutical product and any mention of any commercial brand in this presentation is strictly for educational purposes.
This video gives a quick introduction to ultra-long half-life (UHL) clotting factor replacement therapy. Learn more about different treatment options
The 3rd edition of the WFH laboratory Manual is the definitive how-to guide for the accurate diagnosis of hemophilia and
Listen to this 90-minute webinar presented on March 7, 2025, to learn about women and girls with bleeding disorders (WGBD).
The Report on Annual Global Survey (AGS) includes demographic and treatment data, providing a global snapshot of people with hemophilia,
This patient handbook contains basic information about the inheritance, diagnosis, symptoms and management of fibrinogen disorders, including afibrinogenemia, hypofibrinogenemia, dysfibrinogenemia
Publishing in Haemophilia—the official journal of the WFH—presents both opportunities and challenges for researchers and practitioners in the field. While
